Latest Pharma and Biotech News
Biotechnology
22 April 2025 San Diego-based iBio, an AI-driven innovator of precision antibody therapies, has announced a licensing agreement with privately-held US biotech AstralBio.
Today's issue
Refine Search
Pharmaceutical
Shares in Eli Lilly shot up last Thursday after the US pharma major announced positive top-line Phase III results from ACHIEVE-1, comparing orforglipron to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. 23 April 2025
Pharmaceutical
Denmark-based allergy immunotherapy specialist ALK Abello today announced that its Itulazax (tree pollen sublingual allergy immunotherapy tablet) has been approved by the European regulator for treatment of young children and adolescents aged five to 17. 23 April 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja (leniolisib), from Dutch biopharma company Pharming, for reimbursement and use within the National Health Service (NHS) in England and Wales. 23 April 2025
Biotechnology
Autoimmune diseases specialist Immunovant has announced changes to its leadership team and the expanded development of its drug IMVT-1402 into two new indications, Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE). 23 April 2025
Biotechnology
Cambridge, USA-based biotech Repertoire Immune Medicines today announced a collaboration and license agreement with Genentech, a subsidiary of Swiss pharma giant Roche, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. 23 April 2025
Biotechnology
A new report highlights disparities in access to CAR T-cell therapies across Europe, with eligible patient treatment rates as low as 11% in some countries. The analysis suggests that complex care pathways and inconsistent funding models are key barriers to broader use of the treatment. 23 April 2025
Pharmaceutical
The Trump administration is reportedly revisiting a contentious drug pricing strategy that would tie US medicine prices to those paid in other developed nations, according to a Reuters report citing multiple industry sources. 23 April 2025
Biotechnology
South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna over key technologies used in the manufacture of mRNA vaccines. 23 April 2025
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim and Dutch precision oncology company Tessellate Bio have entered into a research collaboration and global license agreement. 23 April 2025
Biotechnology
Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp. 23 April 2025
Pharmaceutical
The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US President Donald Trump’s proposed pharmaceutical tariffs impacting global supply chains. 23 April 2025
Pharmaceutical
US pharma major Bristol Myers Squibb saw its shares fall 4% in after-hours trading on Tuesday, after it announced disappointing top-line results from the Phase III ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. 23 April 2025
Biotechnology
French drug developer Innate Pharma’s shares were up 5.6% at 1.81 euros in early trading after it announced a review of its January 2016 research collaboration and license agreement with Sanofi. 23 April 2025
Generics
The Russian pharma trade group Innovative Pharma (Inpharma) has sent an official letter to the Ministry of Industry and Trade of Russia with proposals for revising the criteria for including drugs in the list of strategically important drugs, The Pharma Letter’s local correspondent reports. 23 April 2025
Biotechnology
US biotech major Regeneron Pharmaceuticals has announced a significant expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of its commercial biologic medicines at its Holly Springs, North Carolina, campus. 22 April 2025
Biotechnology
San Diego-based iBio, an AI-driven innovator of precision antibody therapies, has announced a licensing agreement with privately-held US biotech AstralBio. 22 April 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending the reimbursement of Opdivo (nivolumab) in combination with Yervoy (ipilimumab). 22 April 2025
Biotechnology
US clinical-stage biotech Halda Therapeutics today announced that Dr Eyal Attar has joined the company as chief medical officer (CMO). Dr Attar brings to Halda over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics. 22 April 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi (marstacimab) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35kg with hemophilia A and B. 22 April 2025
Pharmaceutical
Harvard University has filed a lawsuit against the US government after more than $2 billion in federal research funding was suspended, disrupting a range of biomedical and public health projects. The legal challenge, announced Monday, marks an escalation in a standoff with the Trump administration over new policy demands tied to continued grant access. 22 April 2025
All news
Pharmaceutical
Shares in Eli Lilly shot up last Thursday after the US pharma major announced positive top-line Phase III results from ACHIEVE-1, comparing orforglipron to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. 23 April 2025
Pharmaceutical
Denmark-based allergy immunotherapy specialist ALK Abello today announced that its Itulazax (tree pollen sublingual allergy immunotherapy tablet) has been approved by the European regulator for treatment of young children and adolescents aged five to 17. 23 April 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja (leniolisib), from Dutch biopharma company Pharming, for reimbursement and use within the National Health Service (NHS) in England and Wales. 23 April 2025
Biotechnology
Autoimmune diseases specialist Immunovant has announced changes to its leadership team and the expanded development of its drug IMVT-1402 into two new indications, Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE). 23 April 2025
Biotechnology
Cambridge, USA-based biotech Repertoire Immune Medicines today announced a collaboration and license agreement with Genentech, a subsidiary of Swiss pharma giant Roche, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. 23 April 2025
Biotechnology
A new report highlights disparities in access to CAR T-cell therapies across Europe, with eligible patient treatment rates as low as 11% in some countries. The analysis suggests that complex care pathways and inconsistent funding models are key barriers to broader use of the treatment. 23 April 2025
Pharmaceutical
The Trump administration is reportedly revisiting a contentious drug pricing strategy that would tie US medicine prices to those paid in other developed nations, according to a Reuters report citing multiple industry sources. 23 April 2025
Biotechnology
South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna over key technologies used in the manufacture of mRNA vaccines. 23 April 2025
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim and Dutch precision oncology company Tessellate Bio have entered into a research collaboration and global license agreement. 23 April 2025
Biotechnology
Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp. 23 April 2025
Pharmaceutical
The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US President Donald Trump’s proposed pharmaceutical tariffs impacting global supply chains. 23 April 2025
Pharmaceutical
US pharma major Bristol Myers Squibb saw its shares fall 4% in after-hours trading on Tuesday, after it announced disappointing top-line results from the Phase III ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. 23 April 2025
Biotechnology
French drug developer Innate Pharma’s shares were up 5.6% at 1.81 euros in early trading after it announced a review of its January 2016 research collaboration and license agreement with Sanofi. 23 April 2025
Generics
The Russian pharma trade group Innovative Pharma (Inpharma) has sent an official letter to the Ministry of Industry and Trade of Russia with proposals for revising the criteria for including drugs in the list of strategically important drugs, The Pharma Letter’s local correspondent reports. 23 April 2025
Biotechnology
US biotech major Regeneron Pharmaceuticals has announced a significant expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of its commercial biologic medicines at its Holly Springs, North Carolina, campus. 22 April 2025
Biotechnology
San Diego-based iBio, an AI-driven innovator of precision antibody therapies, has announced a licensing agreement with privately-held US biotech AstralBio. 22 April 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending the reimbursement of Opdivo (nivolumab) in combination with Yervoy (ipilimumab). 22 April 2025
Biotechnology
US clinical-stage biotech Halda Therapeutics today announced that Dr Eyal Attar has joined the company as chief medical officer (CMO). Dr Attar brings to Halda over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics. 22 April 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi (marstacimab) to prevent or reduce bleeding in patients 12 years of age and older weighing at least 35kg with hemophilia A and B. 22 April 2025
Pharmaceutical
Harvard University has filed a lawsuit against the US government after more than $2 billion in federal research funding was suspended, disrupting a range of biomedical and public health projects. The legal challenge, announced Monday, marks an escalation in a standoff with the Trump administration over new policy demands tied to continued grant access. 22 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze